Core Viewpoint - The article compares Altria and Philip Morris International, highlighting their differing business models, financial performance, and growth prospects in the tobacco industry, particularly in the context of their transitions to smoke-free products. Business Model Comparison - Altria and Philip Morris, despite sharing cigarette brands, have different business models, with Altria focusing on the U.S. market and Philip Morris on international markets [2][3] - Philip Morris has successfully developed next-generation products like Iqos and Zyn, gaining significant market share, while Altria has struggled with its investments in Juul and cannabis [4][5][6] Financial Performance - In 2024, Altria's revenue declined by 1.9% to $24 billion, primarily due to a 10.2% drop in cigarette shipment volume, although it maintained a high adjusted operating margin of 61.2% [8][9] - Philip Morris reported a 7.7% increase in revenue to $37.9 billion, with a 0.6% rise in international cigarette volume and a 16% increase in operating income [9] Dividend and Valuation - Altria offers a dividend yield of 7% and trades at a price-to-earnings ratio of 11.3, maintaining a strong reputation as a dividend payer [10][11] - Philip Morris has a lower dividend yield of 3.5% but a higher P/E ratio of 22, reflecting its faster growth and success in next-gen products [11] Growth Prospects - Altria is beginning to see growth from its investment in Njoy, but it continues to face revenue losses and challenges in its core cigarette business [12] - Philip Morris is experiencing growth in both its next-gen products and its cigarette business, indicating a more favorable long-term growth trajectory [12][13]

Core Insights - The ability to generate cash is more critical than net income for evaluating stocks, as non-cash expenses can distort the financial picture [1] - Free cash flow margin is a key profitability metric that indicates a company's ability to convert sales into cash available for shareholders [2] Company Summaries Altria Group - Altria Group leads the U.S. large-cap consumer staples sector with a free cash flow margin exceeding 42%, significantly higher than Philip Morris International's 28% [3] - The company's strong cash flow generation supports a high dividend yield of 6.9%, ranking it among the top 20 dividend yields in U.S. large-cap stocks [3] Airbnb - Airbnb has a free cash flow margin of just under 41%, leading the U.S. large-cap consumer discretionary sector [6] - The company's free cash flow increased by 108% from 2021 to 2024, reaching $4.5 billion, with a notable turnaround from a loss of $225 million in 2021 to a profit of $2.6 billion in 2024 [6][7] - A significant $1.9 billion difference exists between Airbnb's net income and free cash flow, primarily due to $1.4 billion in stock-based compensation [7] - Despite concerns about stock-based compensation diluting shares, Airbnb has engaged in $3.4 billion in buybacks to mitigate this effect, reducing its fully diluted share count by over 5% since December 2022 [8][9] Texas Pacific Land - Texas Pacific Land boasts a free cash flow margin of over 65%, the highest among U.S. large-cap stocks in the energy sector [10] - The company's royalty business model allows it to profit from leasing land rights for oil extraction without incurring the costs of extraction [11]

Market Overview - The stock market began 2025 strong but has recently faced challenges due to trade wars and tariffs, with the S&P 500 down nearly 4.5% year to date [1] CVS Health - CVS Health has seen a significant increase of approximately 51% in 2025, boosted by better-than-expected year-end earnings and guidance in line with Wall Street expectations [3][4] - The company had a difficult previous year, with shares dropping by 43%, leading to a change in CEO, which has contributed to improved investor sentiment [4][5] - Despite the positive performance, CVS faces high medical costs and uncertainty in the healthcare sector, with a current valuation of 18 times trailing earnings, indicating it is not overly expensive [5][6] Super Micro Computer - Super Micro Computer's stock has risen by 26.5% in 2025, recovering from previous concerns about its financial statements and auditor issues [7][8] - The company successfully filed its financial statements on time with a new auditor, alleviating fears of delisting, and is benefiting from increased demand for IT infrastructure driven by AI developments [8] - However, the company reported a gross profit of $2.1 billion on sales of $14.9 billion, indicating thin margins, and potential risks from economic conditions and tariffs [9] Philip Morris International - Philip Morris International's shares increased by 27.9% in 2025, following better-than-expected guidance for adjusted earnings per share [10] - The stock received a boost from regulatory approval to market its nicotine pouch, Zyn, in the U.S., although concerns remain about the health implications of such products [11][12] - Despite the positive start to the year, the stock trades at 25 times earnings, raising questions about its long-term viability in a declining tobacco market [12]

Economic Outlook - The U.S. economy is showing signs of potential recession, with the Atlanta Federal Reserve predicting a 2.1% decline in Q1 GDP after earlier forecasts of over 2% growth [1] Walmart - Walmart is positioned as a top defensive stock, having gained 2% during the Covid recession while the S&P 500 lost 25%, and rose 12% during the Great Recession of 2008-2009 [2][3] - The company benefits from its size and scale, providing significant buying power that allows it to be a price leader during economic downturns [4] - Walmart's extensive reach means 90% of the U.S. population lives within 10 miles of a store, which supports its Walmart+ membership growth, particularly among wealthier consumers [5] - Upper-income households, defined as those earning $100,000 or more, have been a key growth driver for Walmart, potentially increasing their patronage during a recession [6] - Walmart is also expanding its advertising and online marketplace businesses, enhancing fulfillment capabilities for third-party merchants [7] Philip Morris International - Philip Morris International's traditional cigarette business remains strong, with modest volume growth and strong pricing power, particularly in international markets [8] - The company's smokeless products, such as Zyn and IQOS, are significant growth drivers, with Zyn projected to see volume growth of 34% to 41% this year [9] - IQOS has also experienced solid growth, with plans for broader rollout in the U.S. pending FDA approval [10] - Zyn and IQOS offer better unit economics compared to traditional cigarettes, with Zyn's contribution level being six times greater and IQOS's twice as good [11] - The addictive nature of Philip Morris' products makes them resilient during economic downturns, and the company offers a 3.5% dividend yield, making it an attractive growth stock in a defensive industry [12]

Kroger Company Overview - Kroger's interim CEO Ron Sargent has taken over following the resignation of Rodney McMullen, with no mention of McMullen during the earnings call, indicating a focus on future performance rather than past leadership [3][4] - The company reported identical sales growth of 2.4% and generated $1.4 billion in operating profit from alternative profit businesses, which account for over a quarter of its operating income [4][6] - Digital sales are growing at 10%, highlighting the competitive landscape in retail where convenience is becoming as important as price [5][6] Stock Performance and Shareholder Returns - Kroger's stock has increased by approximately 12% since the failed merger with Albertsons, with a total increase of 30% over the past year, despite flat to declining adjusted earnings per share [7][8] - The company is committed to a total shareholder return of 8-11%, with a current dividend yield of about 2% [8] Abercrombie & Fitch Company Overview - Abercrombie & Fitch reported a 16% increase in sales for the full year 2024, but the growth rate is slowing, with comparable sales for the Abercrombie brand only increasing by 5% in the fourth quarter [9][10] - The company expects consolidated sales growth of 3-5% for 2025, which is below market expectations, and operating margins are anticipated to be lower than previously expected [10][11] Inventory and Market Concerns - Abercrombie's inventory has increased by over $100 million, raising concerns about slowing demand and potential misalignment with consumer trends [12][13] - The company has a valuation of about eight times earnings, indicating market perception of limited growth potential [14] Turning Point Brands Overview - Turning Point Brands is experiencing growth in the hemp market due to the adoption of Farm Bill compliant products, with an estimated 7,000 retail outlets in Texas selling hemp-derived products [15][16] - The company is also focusing on modern oral nicotine products, with a projected revenue growth of 56% in 2025 compared to the previous year [19][20] Intuitive Surgical Overview - Intuitive Surgical's da Vinci Surgical System allows surgeons to perform minimally invasive surgeries with enhanced precision, primarily in urology and gynecology [23][24] - The company has invested nearly 14% of its revenue in R&D, indicating a commitment to innovation amid growing competition in the robotics field [31][32] - Intuitive Surgical has maintained a near-monopoly in the market, leveraging its established systems and easier regulatory pathways for new products [33]

Core Insights - The interconnectedness of today's markets necessitates that investors stay informed about the relationships between different asset classes [1] - A spike in S&P 500 volatility has led to increased bond prices, which in turn lowers yields, making other assets more attractive [2][3] - Dividend-focused investments are becoming increasingly valuable as alternatives to bonds, particularly in the current market environment [4][5] Investment Opportunities - The Schwab US Dividend Equity ETF (SCHD) has seen significant institutional capital inflow, with $13 billion invested over the past quarter, indicating strong demand for dividend income amid market volatility [5][6] - Realty Income Co. offers a monthly dividend payout of $3.21 per share, translating to an annualized yield of 5.66%, making it an attractive option for income-focused investors [8][10] - Altria Group Inc. has a dividend yield of 7.01% with a strong track record of dividend increases over 56 years, despite recent sluggish retail sales data [12][15] Market Dynamics - The current bond yields are approaching 4.0%, making dividend-paying stocks like SCHD and Realty Income more appealing [6][7] - Realty Income's stock has shown resilience, trading at 95% of its 52-week high, indicating bullish market sentiment despite a flat performance over the past year [14] - Altria's low beta of 0.6 suggests it is less volatile than the S&P 500, providing a defensive investment option in uncertain market conditions [14][15]

Core Viewpoint - Altria Group, Inc. is navigating a challenging market by balancing its traditional tobacco business with a strategic shift towards smoke-free alternatives, despite facing pressures in its core Smokeable Products segment due to declining volumes [1][10]. Transition to Smoke-Free Products - A significant part of Altria's growth strategy involves transitioning to reduced-risk products like e-vapor and heated tobacco alternatives, responding to consumer demand for healthier options [3]. - NJOY, a key component of Altria's transformation, expanded its distribution to over 100,000 stores in 2024, achieving a 15% growth in consumable shipments during the fourth quarter, with a retail share of 6.4%, up 2.8 points year-over-year [4]. Operational Initiatives - Altria has launched the "Optimize & Accelerate" initiative to modernize operations, aiming for cumulative cost savings of at least $600 million over five years through enhanced efficiency and the use of generative AI and automation [6]. Market Challenges - The cigarette industry is experiencing significant challenges, with shipment volumes declining due to macroeconomic pressures and the rise of illegal disposable e-vapor products, which have led to a shift from cigarettes to these alternatives [7][8]. - Altria's revenues from the Smokeable Products segment have been declining for several quarters, influenced by inflation and reduced discretionary spending among adult smokers [8][9]. Competitive Landscape - The growth of illicit flavored disposable e-vapor products poses a substantial threat to Altria's efforts in the smoke-free category, overshadowing NJOY's market share growth [9][10]. - Altria's stock has gained 5.7% over the past three months, compared to the industry's growth of 13.3% [11].

Core Insights - Altria and British American Tobacco offer attractive yields of 7.4% and 7.7% respectively, significantly higher than the S&P 500's 1.2% and the average consumer staples yield of 2.7% [1] - Both companies face a long-term decline in cigarette volumes, with Altria experiencing a more severe decline compared to British American Tobacco [2][4] Volume Trends - Altria's cigarette volume declined by 9.7% in 2022, 9.9% in 2023, and is projected to decline by 10.2% in 2024, indicating a worsening trend [3] - British American Tobacco's volume declined by 5.1% in 2022, 5.3% in 2023, and 5% in 2024, with the latter two figures excluding the impact of the sale of its Russian and Belarus businesses [4] Business Strategies - Both companies have responded to declining volumes by raising prices, which has allowed them to maintain and even grow dividends despite losing customers [5] - British American Tobacco's global diversification has helped mitigate the impact of volume declines, but it has acknowledged significant challenges in the U.S. market [6] Future Outlook - The tobacco industry faces a bleak future unless new growth platforms are identified to replace declining cigarette operations [7] - Both companies are exploring new business opportunities, such as vaping and pouches, to address the challenges posed by declining cigarette sales [8] Investment Considerations - For short-term income investors, British American Tobacco may be the preferred choice due to its higher yield and better volume performance [9] - Long-term investors may find both companies lacking in fundamental strength to justify investment in the tobacco sector [9]

Core Viewpoint - The market has reacted negatively to recent tariff news and economic data indicating a slowing consumer, yet companies like Coca-Cola, Philip Morris, and Johnson & Johnson have shown resilience and strength in their stock performance during this period [1][18]. Coca-Cola (KO) - Coca-Cola exceeded consensus EPS and sales expectations with growth rates of 12% and 6% respectively, and its gross margin has improved from early 2023 lows [4]. - The company gained market share in the nonalcoholic ready-to-drink beverage sector in North America, with an impressive 11% increase in overall price/mix during FY24 [7]. - Coca-Cola has a 4% five-year annualized dividend growth rate, reinforcing its status as a Dividend King [8]. Philip Morris (PM) - Philip Morris reported a 14% growth in EPS and a 7% increase in sales, with strong demand for its products and a focus on innovation [10]. - The company’s smoke-free products surpassed 40 billion units for the first time in FY24, with net revenues for its Smoke-free Business increasing by 14.2% [11]. - PM has a market-beating annual dividend yield of 3.5% and is expected to see an 8.9% year-over-year earnings growth in FY25 [12]. Johnson & Johnson (JNJ) - Johnson & Johnson shares have shown modest growth of 5% over the past three years, compared to the S&P 500's 46% gain, but the stock's stability is a key takeaway [13]. - The company is also a Dividend King, with a 3.0% annual yield and a 5.5% five-year annualized dividend growth rate [15]. - JNJ's strong cash-generating capabilities and consistent pipeline have positioned its shares favorably, leading to a positive post-earnings movement [17].

Financial Data and Key Metrics Changes - Revenue increased 13% to $93.7 million for Q4 2024, and full-year sales were up 11% to $360.7 million [6][25] - Adjusted EBITDA for Q4 increased 5% to $26.2 million, while full-year adjusted EBITDA rose 12% to $104.5 million [7][27] - Gross margin for the full year decreased by 39 basis points to 55.9%, and for Q4, it was 56%, down 108 basis points year over year [25][27] Business Line Data and Key Metrics Changes - Zig Zag sales increased 7% year over year to $192.4 million, with Q4 sales up 2% to $45.9 million [27][28] - Stoker's net sales increased 16% year over year to $168.3 million, with Q4 sales up 26% to $47.8 million [28] - Modern oral revenue included a 419% increase in Free sales to approximately $6.3 million for Q4, reflecting strong growth [14][32] Market Data and Key Metrics Changes - Nearly 75% of Americans now live in states with legal regulated cannabis, expanding the total addressable market (TAM) for related products [12] - Stoker's MST volume was up 10 basis points despite a category volume decline of 6.4%, with market share growing by 50 basis points year over year to 7.6% [29][30] Company Strategy and Development Direction - The company is focusing on growth opportunities in its core business after divesting the CDS segment, which is now classified as discontinued operations [4][6] - The goal is to achieve a 10% market share in the modern oral category, with significant investments planned for sales and marketing [8][34] - The company aims to leverage cross-selling opportunities between its modern oral products and Zig Zag portfolio [11][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth momentum across the organization and initiated 2025 adjusted EBITDA guidance of $108 million to $113 million [8][34] - The company is confident in the performance of its modern oral brands, particularly Free and Out, and plans to expand distribution and marketing efforts [19][20] Other Important Information - The company ended the quarter with over $46 million in cash and reported free cash flow of $56.3 million for the year [32] - Capital expenditures for 2024 were $4.6 million, with a budgeted range of $4 to $5 million for 2025 [36] Q&A Session Summary Question: Outlook for modern oral products in national convenience store chains - Management is in discussions with partners and has rolled out a regional partnership with 7-Eleven, showing early positive results [40][43] Question: Growth and distribution opportunities for Stoker's MST - Management believes there are synergies between MST and modern oral products, presenting opportunities for cross-selling [45][47] Question: Drivers of guidance for modern oral products - Guidance is based on expected growth for Free and early reorder rates, with both Free and Out seen as synergistic [50][52] Question: Contribution margin and manufacturing considerations - Gross profit margins for modern oral are in the mid-thirties, with plans to reinvest profits into sales and marketing [56][58] Question: Regulatory environment regarding nicotine products - Management views recent regulatory actions as positive and is not currently concerned about nicotine strength regulations [62][64] Question: Direct-to-consumer opportunities in the nicotine patch category - Management sees a strong online opportunity for Out, while Free will focus on brick-and-mortar channels [65][67] Question: Marketing strategies for Free and Out - The company plans to leverage both online and brick-and-mortar strategies to maximize reach across its brand portfolio [71][73] Question: Zig Zag's growth and margin profile - Zig Zag is expected to see single-digit growth, with a mix shift into lower-margin products anticipated to continue [75][78]